Vet-Stem, Inc. develops therapies in veterinary medicine. It develops therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in animals. The company provides laboratory services that enable veterinarians to utilize regenerative cells in animals; and autologous regenerative cells turnaround, vet to vet consultation, and cell banking services. It also offers veterinarian consultation, educational presentations, collection and shipping system, training materials, protocols and information for utilization of regenerative cell therapy, and literature references and background information services. The company serves animal own...
12860 Danielson Court
Poway, CA 92064
Founded in 2002
Aratana Therapeutics, Inc. Enters into Exclusive License Agreement with Vet-Stem, Inc., for its Novel, Allogeneic Stem Cell Therapy Technology
Jun 12 14
Aratana Therapeutics, Inc. announced it has entered into an exclusive license agreement with Vet-Stem, Inc., for its novel, allogeneic stem cell therapy technology. Under the agreement, Aratana obtains exclusive rights to commercialize Vet-Stem's allogeneic stem cells in the United States, which if approved, will be the first FDA-regulated, 'off the shelf' regenerative cell therapy for the treatment of osteoarthritis in dogs. Vet-Stem has now developed a technology platform for producing allogeneic stem cell therapies, where a single donor sample can be used to generate a large bank of doses that can be stored and used to treat multiple patients. Aratana has licensed this allogeneic therapy, which will be tested for safety and efficacy in randomized, placebo-controlled dogs with osteoarthritis and submitted to the FDA for approval. Under the terms of the agreement, Aratana will have an exclusive license to develop and commercialize products in the U.S., based upon Vet-Stem Technology for the treatment of pain and inflammation of canine osteoarthritis. Vet-Stem will continue to be responsible for the ongoing development of its allogeneic stem cell technology. Aratana will pay $500,000 upon signing of the license as a reimbursement to Vet-Stem for a portion of its past development expenses and will be responsible for funding future budgeted development. Aratana will also pay up to $4.5 million in success-based development and regulatory milestones, as well as tiered royalties upon potential commercialization of the stem cell therapy, based on potential sales. Aratana will also have the exclusive right to negotiate expansion of the agreement to include the European Union countries during the calendar year of 2014.
Vet-Stem, Inc. Signs License Agreement with Human Stem Cell Company
Apr 28 14
Vet-Stem, Inc. entered into a non-exclusive European license agreement with a human stem cell company. Under the terms of the agreement, the license provides access to the newly issued Vet-Stem patent for the extraction methods and the use of adipose-derived stem cells in prevention and treatment of diseases in the human.